Research On The Impact Of Technological Innovation In Pharmaceutical Industry On Diversification And Enterprise Performance

After the Nineteenth National Congress,"Healthy China" strategy promotes pharmaceutical enterprises to enhance their ability of technological innovation and increase their R&D investment in technological innovation.However,technological innovation has a long and difficult period from the start of research to the guidance of production stage,and the differences of enterprise scale,capital and technology level restrict the development of patent technology.In order to obtain technological innovation,enterprises choose different forms of diversification.This paper studies the related diversified development of Shuanglu company and the non-related diversified development of Lepu company.It analyses the difference of R&D resources utilization in the innovation stage of technology analysis,and its impact on diversification and enterprise performance,with a view to providing reference for other enterprises in technological innovation.This paper uses case study method.Firstly,reviewing the process of medical reform and technological innovation,the author analyzed the development and influence mechanism of patent and GMP certification in technological innovation of pharmaceutical industry,and found that the level of patent affects the level of innovation,while the speed of equipment,personnel and process upgrading in GMP certification affects the process of innovation.Then,the impact of technological innovation on diversification and enterprise performance is analyzed theoretically,and verified by the case analysis of Shuanglu and Lepu Company.The conclusions of this paper are as follows: 1.Fast innovation process is conducive to related diversification of enterprises,saving production costs 2.Slow technological process,avoiding being eliminated by the market,enterprises obtain new profit opportunities and patent technology from outside,and choose.Non-related diversification can prolong the life cycle of enterprises.3.By choosing high-level patent processing,increasing R&D investment and increasing R&D projects,enterprises can eliminate the negative impact of innovation,thus speeding up the process of innovation and improving enterprise performance.Finally,this paper puts forward policy recommendations: non-related diversified enterprises,slow innovation process,technological innovation choice and cooperation with universities to solve the problem of insufficient R&D personnel and patents.In addition to independent R&D,related diversified enterprises can also cooperate with enterprises with advanced technology to achieve resource sharing,accelerate the process of innovation,and ensure the sustainability of technological innovation.When the direction of technology investment is not clear,enterprises should consider eliminating the influence of adverse factors to ensure the improvement of enterprise performance.